Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-108.53	-104.7	-101.07	-85.81	-52.24	-32.33
Depreciation & Amortization	4.7	4.73	3.54	2.23	1.93	0.45
Share-Based Compensation	24.78	25.26	22.85	16.45	5.77	1.92
Other Operating Activities	-5.22	-6.35	42.81	0.22	2.33	-1.1
Operating Cash Flow	-84.28	-81.07	-31.87	-66.91	-42.22	-31.06
Capital Expenditures	-1.46	-1.62	-3.96	-1.2	-1.05	-1.63
Change in Investments	64.31	107.56	-41.92	-75.23	0	0
Investing Cash Flow	62.85	105.95	-45.88	-76.43	-1.05	-1.63
Share Issuance / Repurchase	9.67	53.01	46.41	1.29	108.59	152.23
Other Financing Activities	-	-	0	-0	-0.49	-2.47
Financing Cash Flow	9.67	53.01	46.41	1.28	108.11	149.76
Net Cash Flow	-11.76	77.89	-31.34	-142.05	64.84	117.07
Free Cash Flow	-85.74	-82.68	-35.83	-68.11	-43.27	-32.69
Free Cash Flow Margin	-1092.93%	-941.72%	-288.82%	-	-	-
Free Cash Flow Per Share	-1.85	-1.88	-0.92	-1.85	-1.29	-1.82

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).